Show simple item record

dc.contributor.authorGill, Dipender
dc.contributor.authorBurgess, Stephen
dc.date.accessioned2022-03-07T02:04:31Z
dc.date.available2022-03-07T02:04:31Z
dc.date.issued2022-02
dc.identifier.issn1549-1277
dc.identifier.otherPMC8812877
dc.identifier.other35113864
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334718
dc.description.abstractDipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.
dc.languageeng
dc.publisherPublic Library of Science (PLoS)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101231360
dc.sourceessn: 1549-1676
dc.subjectHumans
dc.subjectColorectal Neoplasms
dc.subjectAntihypertensive Agents
dc.subjectAngiotensin-Converting Enzyme Inhibitors
dc.subjectRisk Factors
dc.subjectBlood Pressure
dc.subjectGenetic Variation
dc.subjectGenome-Wide Association Study
dc.subjectMendelian Randomization Analysis
dc.titleThe evolution of mendelian randomization for investigating drug effects.
dc.typeArticle
dc.date.updated2022-03-07T02:04:31Z
prism.issueIdentifier2
prism.publicationNamePLoS Med
prism.volume19
dc.identifier.doi10.17863/CAM.82136
dcterms.dateAccepted2022-02-03
rioxxterms.versionofrecord10.1371/journal.pmed.1003898
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidGill, Dipender [0000-0001-7312-7078]
dc.contributor.orcidBurgess, Stephen [0000-0001-5365-8760]
dc.identifier.eissn1549-1676
pubs.funder-project-idWellcome Trust (204623/Z/16/Z)
pubs.funder-project-idMedical Research Council (MC_UU_00002/7)
cam.issuedOnline2022-02-03


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International